PubHawk
RMD Open February 2024 PMID 38388171

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.

Laura C Coates, Robert Landewé, Iain B McInnes, Philip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana-Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya

Full text PDF Download social card

Mentions

10
Peak: 4 in Apr 2024
across 2 sources since Feb 2024

Extended reach

12,074
potential audience

Total likes

14

Video views

917

Mentions per month

Feb 2024 – Aug 2024

Where it's discussed

  • X / Twitter9 posts
  • YouTube1 videos

AI synopsis

What people are saying

The overall tone suggests a shared recognition of the study’s significance, as seen in references to detailed slide decks and clinical insights like 'latest detailed slide deck' and '52-week safety & efficacy data,' which demonstrate an active interest in understanding the research's implications. The tone is professional and informational, emphasizing the study’s contribution to ongoing discussions in the medical community.

AgreementModerate agreement

Most discussions acknowledge the importance of the study and its positive outcomes, reflecting general support.

InterestModerate interest

Participants show moderate curiosity, primarily through references to slides, detailed data, and clinical implications, indicating some engagement but not overwhelming enthusiasm.

EngagementModerate engagement

The posts include calls to action, such as visiting forums and reviewing detailed data, demonstrating a proactive but measured level of involvement.

ImpactModerate impact

The discussions highlight the study’s potential influence on clinical practice and future research, though they mainly serve informational purposes.

Abstract in brief

  • This study evaluated the safety and effectiveness of bimekizumab over 52 weeks for patients with active psoriatic arthritis who had not responded well to previous treatments.
  • In the trial, 347 out of 400 patients completed the study, showing a low incidence of severe adverse events, though some mild to moderate cases, like COVID-19 and oral candidiasis, were reported.
  • Bimekizumab demonstrated significant improvements in patient outcomes, with over half of those on the treatment experiencing at least a 50% improvement in symptoms and many achieving complete skin clearance by week 52.
Read the full abstract

Top posts

Most liked on X and Bluesky
RMD Open
@bmj_rmdopen · X

Aug 24, 2024 · 7 likes · 3 shares · 664 followers View post →
Joseph Merola, MD MMSc
@JosephMerolaMD · X

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL https://t.co/95CaC0s3cU

Feb 23, 2024 · 3 likes · 1 share · 1,666 followers View post →
Alberto Giraldo
@alb_giraldo · X

RT @bmj_rmdopen:

Aug 24, 2024 · 3 shares · 4,397 followers View post →
Immune-Mediated Inflammatory Disease Forum
@TheIMIDForum · X

Want to get more insights from the Phase 3 BE COMPLETE and BE VITAL trials? Head on over to the #IMIDforum where we have just posted the latest detailed slide deck by Coates L, et al: https://t.co/3h0NgZkgzN

Apr 15, 2024 · 1,281 followers View post →
Immune-Mediated Inflammatory Disease Forum
@TheIMIDForum · X

Coates L, et al’s 52-week safety & efficacy data for bimekizumab in TNFi-IR is now live over on the #IMIDforum! Head over there now to get all the clinical details: https://t.co/oNR24dP0ZU

Apr 8, 2024 · 1,281 followers View post →
Immune-Mediated Inflammatory Disease Forum
@TheIMIDForum · X

The latest research by Coates L, et al. aimed to assess 52-week #safety and #efficacy of bimekizumab in patients with active #PsA and prior IR/intolerance to #TNFi. Get all the insights with our detailed slide deck only on the #IMIDforum: https://t.co/vsqEe6oZa6

Apr 3, 2024 · 1,281 followers View post →

All mentions

Dr. Che-Tzu Chang, MD, MS (AIR Jack)
@ILoveWen0224 · X

RT @bmj_rmdopen:

Aug 27, 2024 · 3 shares · 58 followers View post →
Alejandro Martinez Muñoz
@ale_mmzgonc · X

RT @bmj_rmdopen:

Aug 24, 2024 · 3 shares · 423 followers View post →
Alberto Giraldo
@alb_giraldo · X

RT @bmj_rmdopen:

Aug 24, 2024 · 3 shares · 4,397 followers View post →
RMD Open
@bmj_rmdopen · X

Aug 24, 2024 · 7 likes · 3 shares · 664 followers View post →
Immune-Mediated Inflammatory Disease Forum
@TheIMIDForum · X

Want to get more insights from the Phase 3 BE COMPLETE and BE VITAL trials? Head on over to the #IMIDforum where we have just posted the latest detailed slide deck by Coates L, et al: https://t.co/3h0NgZkgzN

Apr 15, 2024 · 1,281 followers View post →
Immune-Mediated Inflammatory Disease Forum
@TheIMIDForum · X

Coates L, et al’s 52-week safety & efficacy data for bimekizumab in TNFi-IR is now live over on the #IMIDforum! Head over there now to get all the clinical details: https://t.co/oNR24dP0ZU

Apr 8, 2024 · 1,281 followers View post →
Immune-Mediated Inflammatory Disease Forum
@TheIMIDForum · X

The latest research by Coates L, et al. aimed to assess 52-week #safety and #efficacy of bimekizumab in patients with active #PsA and prior IR/intolerance to #TNFi. Get all the insights with our detailed slide deck only on the #IMIDforum: https://t.co/vsqEe6oZa6

Apr 3, 2024 · 1,281 followers View post →
PPACMANclinics
@PPACMANgroup · X

RT @JosephMerolaMD: Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis fact…

Feb 27, 2024 · 1 share · 79 followers View post →
Joseph Merola, MD MMSc
@JosephMerolaMD · X

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL https://t.co/95CaC0s3cU

Feb 23, 2024 · 3 likes · 1 share · 1,666 followers View post →